Grifols agreed the deal five years after supplying $50m in equity and development financing for the neurodegenerative disease therapy developer.
Pharmaceutical firm Grifols agreed yesterday to acquire one of its portfolio companies, US-based neurodegenerative disease drug developer Alkahest, for $146m in cash.
Spun out of Stanford University in 2014, Alkahest is working on therapies based on the company’s map of the human plasma proteome – the set of proteins located in a person’s blood plasma – to slow detrimental biological processes of ageing.
The company has four product candidates currently in a total of six phase 2 trials, covering neurodegenerative,…
